Jeremy Thompson, MD
Pain Medicine · Saint Louis, MONPI 1295396844
Payments from drug & device makers
What this record shows
The money is spread across several categories — travel and lodging (45.6%), food and beverage and grants — rather than concentrated in one kind of arrangement. 12 manufacturers reported payments, led by Abbott at 39.0% of the total. Reporting peaked in 2023 at $6,251 and has fallen 95.1% since, to $304 in 2025.
Across 55 payments — averaging $201.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$4K
- Medtronic$4K
- Boston Scientific$2K
- Stryker$592
- Nevro Corp.$145
- Saluda Medical Americas, Inc.$121
- plus $232 from 6 others
What the payments were for
- Grants$3,00027%
- Travel & lodging$5,06246%
- Food & beverage$3,03727%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 25 | $4,332 |
| Medtronic | 10 | $4,003 |
| Boston Scientific | 9 | $1,674 |
| Stryker | 3 | $592 |
| Nevro Corp. | 1 | $145 |
| Saluda Medical Americas, Inc. | 1 | $121 |
| MML US, Inc. | 1 | $93 |
| Pacira Pharmaceuticals Incorporated | 1 | $39 |
| Vertos Medical, Inc. | 1 | $36 |
| Bioventus LLC | 1 | $25 |
| SPR Therapeutics, Inc | 1 | $20 |
| Nalu Medical, Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- PROCLAIM$3,553
- SYNCHROMEDII$3,115
- GENERAL - THERAPIES$910
- INTELLIS ADAPTIVESTIM$850
- EVEREST SPINAL SYSTEM$502
- Senza$145
- Evoke$121
How this compares
$11,099 in reported general payments places this provider in the 80th percentile of 124 pain medicine providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 26 | $937 |
| Pregabalin | 31 | $568 |
| Gabapentin | 33 | $450 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 16 | $372 |
| Baclofen | 20 | $342 |
| Oxycodone Hcl | 11 | $267 |
| Tramadol Hcl | 34 | $260 |
| Duloxetine Hcl | 15 | $245 |
| Tizanidine Hcl | 12 | $167 |
Paid to pharmacies, not to this prescriber.
Other pain medicine in Saint Louis
- Vinicius Tieppo FrancioSaint Louis$35K
- Jooyoung MaengSaint Louis$25K
- Nabil AhmadSaint Louis$21K
- Katharine GurbaSaint Louis$18K
- Alexander BeyzerSaint Louis$11K
- Hamed SadeghipourSaint Louis$10K
- Hess PanjetonSaint Louis$6K
- Xiaobin YiSaint Louis$6K
- Nicole ShinSaint Louis$6K
- Satish ReddySaint Louis$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.